Möchten Sie immer auf dem neuesten Stand bleiben?
Erstellen Sie noch heute ein Leserkonto, um die Branchen und Unternehmen zu verfolgen, die Sie interessieren, und passen Sie Ihr Nachrichten-Dashboard an.
-
New publication identifies neuromuscular junction transmission failure as a novel mechanism contributing to sarcopenia, with preclinical studies showing that ClC-1 inhibition improves neuromuscular...
-
New publication identifies neuromuscular junction transmission failure as a novel mechanism contributing to sarcopenia, with preclinical studies showing that ClC-1 inhibition improves neuromuscular...
-
NorthStrive Biosciences Announces Positive Results from Phase III of AI-Driven Drug Discovery Program with Yuva Biosciences
-
NorthStrive Biosciences Files Two New U.S. Patent Applications Targeting Muscle Preservation in GLP-1 and Next-Generation Obesity Treatment Markets
-
UPDATED: NorthStrive Biosciences Files New U.S. Patent Application Covering EL-22 Formulations and Dosing for Treatment of Muscle-Wasting Conditions relate
-
NorthStrive Biosciences Files New U.S. Patent Application for EL-22 Targeting Muscle Preservation in Humans
-
New York, USA, April 24, 2025 (GLOBE NEWSWIRE) -- Sarcopenia Clinical Trial Pipeline Appears Robust With 18+ Key Pharma Companies Actively Working in the Therapeutics Segment | DelveInsight The...
-
New York, USA, Sept. 25, 2024 (GLOBE NEWSWIRE) -- Sarcopenia Market Anticipates Impressive Growth Trajectory Across 7MM During the Study Period (2020–2034) | DelveInsight The sarcopenia market...
-
PRESS RELEASE NMD Pharma Initiates an Observational Pilot Study Investigating the Effects of Sarcopenia on Neuromuscular Transmission in Older Adults Aarhus, Denmark, 1 June 2021 – NMD Pharma A/S,...
-
PRESS RELEASE NMD Pharma Initiates an Observational Pilot Study Investigating the Effects of Sarcopenia on Neuromuscular Transmission in Older Adults Aarhus, Denmark, 1 June 2021 – NMD Pharma A/S,...